Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + DCF for Neoadjuvant ESCC
NCT06463834Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Cancer Hospital. Started Mar 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06463834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463834.